Disco Pharmaceuticals raised €36M in seed funding to advance therapies for hard-to-treat tumors, co-led by Ackermans and van Haaren and NRW.Bank.
PRIVATEDec 11, 2025
Amount Raised
€36 Million
Round Type
Seed
CologneBiotechnologyHealth Care
Investors
AbbVie VenturesSofinnova PartnersM VenturesPanakes PartnersAckermans And Van HaarenNrw.Bank
Description
Disco Pharmaceuticals, based in Cologne, raised €36M in seed funding. The round was co-led by Ackermans and van Haaren and NRW.Bank, with participation from existing investors. The funds will advance multiple lead antibody-drug conjugates toward IND-enabling studies. The company also appointed Mark Manfredi, Ph.D., as CEO.
Who to call at Disco Pharmaceuticals, and when
A new round usually means Disco Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Disco Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Disco Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Disco Pharmaceuticals. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Disco Pharmaceuticals
Location
Cologne, North Rhine Westphalia, Germany
About
DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Disco Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CologneBiotechnologyHealth Care